Оптимизация подхода к лечению и прогнозированию осложнений доброкачественной гиперплазии предстательной железы

Оптимизация подхода к лечению и прогнозированию осложнений доброкачественной гиперплазии предстательной железы

Автор: Пикалов Сергей Михайлович, Гусев Денис Олегович, Адилов Аллахверди Дилан Оглы, Зимичев Александр Анатольевич, Климентьева Марина Сергеевна, Сумский Павел Владимирович, Тарасов Иван Валерьевич

Журнал: Вестник медицинского института "РЕАВИЗ": реабилитация, врач и здоровье @vestnik-reaviz

Рубрика: Клиническая медицина

Статья в выпуске: 2 (44), 2020 года.

Бесплатный доступ

Актуальность проблемы терапии доброкачественной гиперплазии предстательной железы обусловлена высокой распространённостью этого заболевания, негативным влиянием на качество жизни пациентов, а также риском развития ряда серьезных осложнений, таких как острая задержка мочеиспускания, острая почечная недостаточность, гематурия и тампонада мочевого пузыря. Необходимо отметить высокие показатели госпитализированной заболеваемости при ДГПЖ. В Нижегородской области госпитализированная заболеваемость составила в 2010 году 462,3 на 100 000 мужчин соответствующего возраста. В 87,1 % случаев госпитализированным пациентам с ДГПЖ выполняется хирургическое лечение. Более половины пациентов с ДГПЖ госпитализируются по экстренным показаниям, при этом в 4,6 % случаев выявляется острая задержка мочи, а в 1,2 % случаев - острая почечная недостаточность.

Еще

Острая задержка мочеиспускания, доброкачественная гиперплазия предстательной железы, лечение консервативное и хирургическое

Короткий адрес: https://sciup.org/143172337

IDR: 143172337

Список литературы Оптимизация подхода к лечению и прогнозированию осложнений доброкачественной гиперплазии предстательной железы

  • Zimichev A.A. Sovershenstvovanie urologicheskih i onkologicheskih metodov profilaktiki i lecheniya raka mochevogo puzyrya: dis.. dokt. med. nauk. - Moskva, 2015. - 272 s.
  • Klinicheskie rekomendacii. Dobrokachestvennaya giperplaziya predstatel'noj zhelezy. God utverzhdeniya: 2019.
  • Ahyai SA, Gilling P, Kaplan SA et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010; 58(3): 384-97.
  • Checcucci E, Autorino R, Cacciamani GE et al.; Uro-technology and SoMe Working Group of the Young Academic Urologists Working Party of the European Association of Urology. Artificial intelligence and neural networks in urology: current clinical applications. Minerva Urol Nefrol. 2019 Dec 12. DOI: 10.23736/S0393-2249.19.03613-0
  • Deng Z, Sun M, Zhu Y et al. Thulium laser VapoResection of the prostate versus traditional transurethral resection of the prostate or transurethral plasmakinetic resection of prostate for benign prostatic obstruction: a systematic review and meta-analysis. World J Urol. 2018; 36(9): 1355-1364.
  • Frankish K, Ramsey WM (eds). Introduction. The Cambridge handbook of artifcial intelligence. Cambridge University Press, Cambridge, 2014. pp 1-14.
  • Goldenberg SL, Nir G, Salcudean SE. A new era: artificial intelligence and machine learning in prostate cancer. Nat Rev Urol. 2019; 16(7): 391-403.
  • Good D.W. et al. Prostate Benign Prostatic Hyperplasia // Blandy's Urology. 2019. P. 531-561.
  • Hamet P, Tremblay J. Artificial intelligence in medicine. Metabolism. 2017; 69S: S36-S40.
  • Han SH, Kim KW, Kim S, Youn YC. Artificial Neural Network: Understanding the Basic Concepts without Mathematics. Dement Neurocogn Disord. 2018; 17(3):83-89.
  • He J, Baxter SL, Xu J et al. The practical implementation of artificial intelligence technologies in medicine. Nat Med. 2019; 25(1): 30-36.
  • Huang SW, Tsai CY, Tseng CS et al. Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. BMJ. 2019; 367: l5919.
  • Ichihara K, Masumori N, Fukuta F et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015; 193(3): 921-6.
  • Inzunza G, Rada G, Majerson A. Bipolar or monopolar transurethral resection for benign prostatic hyperplasia? Medwave. 2018; 18(1): e7134.
  • Iscaife A, Dos Anjos G, Barbosa C Neto et al. The role of bladder diverticula in the prevalence of acute urinary retention in patients with BPH who are candidates to surgery. Int Braz J Urol. 2018; 44(4): 765-770.
  • Izard J, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: two decades of change. BJU Int 2011; 108: 89-93.
  • Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. Journal of Urology. 1997; 158(2): 481-487.
  • Jiang YL, Qian LJ. Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. BMC Urol. 2019; 19(1): 11.
  • Kaplan SA, Lee JY, Meehan AG, Kusek JW; MTOPS Research Group. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol. 2011; 185(4):1369-73.
  • Karavitakis M, Kyriazis I, Omar MI et al. Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. Eur Urol. 2019; 75(5): 788-798.
  • Kenny AG, Pellerin O, Amouyal G et al. Prostate Artery Embolization in Patients With Acute Urinary Retention. Am J Med. 2019;132(11):e786-e790.
  • Kim EH, Brockman JA, Andriole GL. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol. 2018; 5(1): 28-32.
  • Kim JH, Baek MJ, Sun HY et al. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. PLoS One. 2018; 13(10): e0203479.
  • Lourenco T, Shaw M, Fraser C et al. The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials. World J Urol. 2010; 28(1): 23-32.
  • Malling B, Røder MA, Brasso K et al. Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Radiol. 2019; 29(1): 287-298.
  • Mayer EK, Kroeze SG, Chopra S et al. Examining the 'gold standard': a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU Int. 2012; 110(11): 1595-601.
  • McBee MP, Awan OA, Colucci AT et al. Deep Learning in Radiology. Acad Radiol. 2018; 25(11): 1472-1480.
  • Mónica FZ, De Nucci G. Tadalafil for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2019; 20(8): 929-937.
  • Oelke M, Höfner K, Jonas U et al. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol. 2007; 52(3): 827-34.
  • Ramesh AN, Kambhampati C, Monson JR, Drew PJ. Artificial intelligence in medicine. Ann R Coll Surg Engl. 2004; 86(5): 334-8.
  • Ren RM, Kou M, Lan XX. Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis. Chin Med J (Engl). 2010; 123(2): 234-8.
  • Renganathan V. Overview of artificial neural network models in the biomedical domain. Bratisl Lek Listy. 2019; 120(7): 536-540.
  • Roehrborn CG, Siami P, Barkin J et al. CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57:123-31.
  • Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. Rev Urol 2001; 3(4): 187-192
  • Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyper-plasia. Urology. 1994; 43: 284-294.
  • Stuart R, Norvig P (eds) Artifcial intelligence - a modern approach, 3rd edn. Prentice Hall, Upper Saddle River, 2010.
  • Suarez-Ibarrola R, Hein S, Reis G, Gratzke C, Miernik A. Current and future applications of machine and deep learning in urology: a review of the literature on urolithiasis, renal cell carcinoma, and bladder and prostate cancer. World J Urol. 2019 Nov 5.
  • DOI: 10.1007/s00345-019-03000-5
  • Sun F, Sun X, Shi Q, Zhai Y. Transurethral procedures in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications. Medicine (Baltimore). 2018; 97(51): e13360.
  • Tran BX, Vu GT, Ha GH et al. Global Evolution of Research in Artificial Intelligence in Health and Medicine: A Bibliometric Study. J Clin Med. 2019 Mar 14;8(3). pii: E360.
  • Ugare UG, Bassey IA, Udosen EJ et al. Management of lower urinary retention in a limited resource setting. Ethiop J Health Sci 2014; 24(4): 329-336.
  • Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol. 2005; 40(3): 121-8.
  • Wainberg M, Merico D, Delong A, Frey BJ. Deep learning in biomedicine. Nat Biotechnol. 2018; 36(9): 829-838.
  • Wang Y, Bao Y, Liu J et al. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. Low Urin Tract Symptoms. 2018; 10(1): 84-92.
  • Yuan JQ, Mao C, Wong SY et al. Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis. Medicine (Baltimore). 2015; 94(27): e974.
  • Zattoni F, Ficarra V, Novara G. Risk stratification for benign prostatic hyperplasia. Urologia. 2017; 84(3): 153-157.
  • Zhang J, Li X, Yang B et al. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. World J Urol. 2019; 37(1): 143-153.
  • Zhou Z, Cui Y, Wu J et al. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urol. 2019; 19(1): 17.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp